| 1.52 0.16 (11.76%) | 09-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.1 | 1-year : | 2.45 |
| Resists | First : | 1.79 | Second : | 2.1 |
| Pivot price | 1.39 |
|||
| Supports | First : | 1.36 |
Second : | 1.1 |
| MAs | MA(5) : | 1.62 |
MA(20) : | 1.37 |
| MA(100) : | 1.04 |
MA(250) : | 0.78 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 86.4 |
D(3) : | 84.6 |
| RSI | RSI(14): 66.3 |
|||
| 52-week | High : | 1.79 | Low : | 0.3 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ JUPW ] has closed below upper band by 11.9%. Bollinger Bands are 103.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.75 - 1.76 | 1.76 - 1.77 |
| Low: | 1.53 - 1.54 | 1.54 - 1.55 |
| Close: | 1.65 - 1.66 | 1.66 - 1.67 |
Jupiter Wellness, Inc. develops cannabidiol (CBD) based medical therapeutics and wellness products. The company's clinical pipeline includes CaniDermRX (JW-100), a novel topical formulation containing CBD and aspartame for the treatment of eczema, dermatitis, and actinic keratosis; JW-101, a prescription product for the treatment of burns; and JW-200, a non-prescription lotion/lip balm for the treatment of symptoms of cold sores. It also manufactures, distributes, and markets a line of consumer products, such as CBD-infused sunscreen under the CaniSun brand; CBD-infused skin care lotion under the CaniSkin brand; and products for the dermatological treatments of pain and inflammation under the CaniDermRX brand. The company was formerly known as CBD Brands, Inc. Jupiter Wellness, Inc. was incorporated in 2018 and is headquartered in Jupiter, Florida.
Tue, 28 Nov 2023
Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot Previously known as Jupiter Wellness - Yahoo Finance
Fri, 15 Sep 2023
Safety Shot’s stock reverses sharply lower, as hangover remedy company’s name and ticker change take effect - MarketWatch
Thu, 14 Sep 2023
Jupiter Wellness Changes its Name to Safety Shot and Ticker to “SHOT” in Alignment with New Business Focus - GlobeNewswire
Wed, 30 Aug 2023
Jupiter Wellness Responds to Frivolous Claims Made by FSD Pharma and Unauthorized Tagging of its Stock. - Yahoo Finance
Fri, 25 Aug 2023
FSD Pharma Rebuts Claims of GBB Drink Lab now acquired by Jupiter Wellness Inc. Trading under the symbol (NASDAQ: JUPW) - Business Wire
Fri, 18 Aug 2023
UFC Marital Artist and Influencer Hector Lombard Signs on with Jupiter Wellness' Safety Shot - SEC.gov
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 32 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 44.9 (%) |
| Held by Institutions | 18.7 (%) |
| Shares Short | 2,450 (K) |
| Shares Short P.Month | 1,510 (K) |
| EPS | -0.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.2 |
| Profit Margin | -210.2 % |
| Operating Margin | -192 % |
| Return on Assets (ttm) | -56.2 % |
| Return on Equity (ttm) | -153.2 % |
| Qtrly Rev. Growth | -21.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.18 |
| EBITDA (p.s.) | -0.34 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -2.71 |
| PEG Ratio | 0 |
| Price to Book value | 8.11 |
| Price to Sales | 9.28 |
| Price to Cash Flow | -11.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|